• 1
    Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384.
  • 2
    Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010; 11: 430-445.
  • 3
    Musso G, Gambino R, Cassader M, Pagano GF. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649.
  • 4
    van der Poorten D, Milner KL, Hui J. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. HEPATOLOGY 2008; 48: 449-457.
  • 5
    Gastaldelli A, Cusi K, Pettiti M. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007; 133: 496-506.
  • 6
    Park BJ, Kim YJ, Kim DH. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol 2008; 23: 900-907.
  • 7
    Harding AH, Day NE, Khaw KT, Bingham S, Luben R, Welsh A, Wareham NJ. Dietary fat and the risk of clinical type 2 diabetes: the European prospective investigation of Cancer-Norfolk study. Am J Epidemiol 2004; 159: 73-82.
  • 8
    Carmiel-Haggai M, Cederbaun, Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 2005; 19: 136-138.
  • 9
    Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M; for the AlkaMeSy Study Group. Visceral adiposity index (VAI): a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010; 33: 920-922.
  • 10
    Petta S, Amato M, Cabibi D, Cammà C, Di Marco V, Giordano C. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. HEPATOLOGY 2010; 52: 1543-1552.
  • 11
    Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.
  • 12
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
  • 13
    Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict non-alcoholic fatty liver disease. Clin Chem 2007; 53: 686-692.
  • 14
    Nunez C, Gallagher D, Visser M, Pi-Sunyer FX, Wang Z, Heynsfield SB. Bioimpedance analysis: evaluation of leg-to-leg system based on pressare contact footpad electrodes. Med Sci Sports Exerc 1997; 29: 524-531.
  • 15
    Stanforth PR, Jackson AS, Green JS, Gagnon J, Rankinen T, Despres J-P, Bouchard C. Generalized abdominal visceral fat prediction models for black and white adults aged 17-65 y: the Heritage Family study. Intern J Obes 2004; 28: 925-932.
  • 16
    Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009; 48: 1-26.
  • 17
    Musso G, Gambino R, Pacini G, Pagano G, Durazzo M, Cassader M. Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. HEPATOLOGY 2009; 49: 426-435.
  • 18
    Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
  • 19
    Pacher P, Szabo C. Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 2006; 6: 136-141.
  • 20
    Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal 2011; 15: 1325-1365.
  • 21
    O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007; 100: 899-904.
  • 22
    Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001; 24: 539-548.
  • 23
    Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 2007; 30: 89-94.
  • 24
    Musso G, Gambino R, Cassader M. Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis. J Nutr Biochem 2010; 21: 834-840.
  • 25
    Cobelli C, Toffolo GM, Dalla Man C. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007; 293: E1-E15.
  • 26
    Tura A, Kautzky-Willer A, Pacini G. Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT. Diabetes Res Clin Pract 2006; 72: 298-301.
  • 27
    Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49: 755-765.
  • 28
    Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005; 54: 795-802.
  • 29
    Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, Barbieri M, et al. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr 2003; 78: 1135-1140.
  • 30
    Annuzzi G, Bozzetto L, Patti L, Santangelo C, Giacco R, Di Marino L, et al. Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia. Metabolism 2010; 59: 567-574.
  • 31
    Halleux CM, Takahashi M, Del Porte ML, Detry R, Funahashi T, Matsuzawa Y, et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral abdominal tissue. Biochem Biophys Res Commun 2001; 288: 1102-1107.
  • 32
    Brame LA, Considine RV, Yamauchi M, Baron AD, Mather KJ. Insulin and endothelin in the acute regulation of adiponectin in vivo in humans. Obes Res 2005; 13: 582-588.
  • 33
    Mostad IL, Qvistad E, Bjerve KS, Grill VE. Effects of a 3-day low fat diet on metabolic control, insulin sensitivity, lipids, and lipoprotein hormones in Norwegian subjects with hypertriacylglycerolemia and type 2 diabetes. Scand J Clin Lab Invest 2004; 64: 656-574.
  • 34
    Seo JB, Moon HM, Noh MJ, Lee YS, Jeong HW, Yoo EJ, et al. Adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression. J Biol Chem 2004; 279: 22108-22117.
  • 35
    Kondo M, Ugi S, Morino K, Fuke T, Obata T, Yoshizaki T, et al. Postprandial activation of protein kinase Cμ regulates the expression of adipocytokines via the transcription factor AP-2β. Int J Mol Med 2011; 28: 95-100.
  • 36
    Meng X, Kondo M, Morino K, Fuke T, Obata T, Yoshizaki T, et al. Transcription factor AP-2beta: a negative regulator of IRS-1 gene expression. Biochem Biophys Res Commun 2010; 392: 526-532.
  • 37
    Long Q, Lei T, Feng B, Yin C, Jin D, Wu Y, et al. Peroxisome proliferator-activated receptor-gamma increases adiponectin secretion via transcriptional repression of endoplasmic reticulum chaperone protein ERp44. Endocrinology 2010; 151: 3195-3203.
  • 38
    Mollica MP, Lionetti L, Putti R, Cavaliere G, Gaita M, Barletta A. From chronic overfeeding to hepatic injury: role of endoplasmic reticulum stress and inflammation. Nutr Metab Cardiovasc Dis 2011; 21: 222-230.
  • 39
    Fryirs MA, Barter PJ, Appavoo M. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 2010; 30: 1642-1648.
  • 40
    Giacca A, Xiao C, Oprescu AI, Carpentier AC, Lewis GF. Lipid-induced pancreatic β-cell dysfunction: focus on in vivo studies. Am J Physiol Endocrinol Metab 2011; 300: E255-E262.
  • 41
    Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with NAFLD. Hepatology 2011 Dec 10. doi: 10.1002/hep.25539.
  • 42
    Arsov T, Carter CZ, Nolan CJ, Petrovsky N, Goodnow CC, Teoh NC. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Comm 2006; 342: 1152-1159.
  • 43
    Kim SJ, Nian C, McIntosh CH. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 2007; 282: 34139-34147.
  • 44
    Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. HEPATOLOGY 2009; 50: 1087-1093.
  • 45
    Bandsma RH, Lewis GF. Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia. Atherosclerosis 2010; 212: 40-41.
  • 46
    Musso G, Gambino R, Cassader M. Need for a three-focused approach to nonalcoholic fatty liver disease. HEPATOLOGY 2011; 53: 1773.
  • 47
    Musso G, Cassader M, Gambino R. Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for liver histology and cardiovascular risk in NAFLD. HEPATOLOGY 2012. DOI: 10.1002/hep.25677.